Omega-3 Fatty Acids Analysis Service for EPA, DHA, ALA and DPA

Creative Proteomics provides matrix-aware omega-3 fatty acid analysis for biological research, ingredient characterization, food and feed studies, and formulation development. We align the target list, chemical form, reporting basis, sample preparation, and analytical platform before testing.

Target analytes: EPA, DHA, ALA, n-3 DPA, and related omega-3 fatty acids

Analytical routes: GC-FID, GC-MS, or targeted LC-MS/MS selected for the matrix and decision

Reporting options: Relative composition, concentration, mass fraction, totals, and defined ratios

Discuss Your Omega-3 Study

Share your matrix, analytes, sample count, and reporting basis.

×

Our services have earned the trust of companies, schools, and organizations globally, and we remain dedicated to maintaining that trust.

Boston University
University at Buffalo
UMass Medical School
Hawaii Pacific University
Medizinische Fakultät
Louisiana State University
NYU Langone
Nature's Fynd
Dietary supplement manufacturer
  • Service Overview
  • Analytes
  • Methods
  • Workflow
  • Quality Control
  • Why Choose
  • Samples
  • Data Package
  • Applications
  • FAQ
  • Publications

Our Omega-3 Fatty Acid Analysis Service

An omega-3 value is only as useful as the basis behind it. Two studies can report the same analyte and still produce figures that cannot be placed side by side, because the fraction measured, the units used, and the platform applied were never aligned. Defining those three points with the study objective in hand is what makes a result interpretable outside the lab that generated it.

Project Decision Available Options Purpose
Measurement scope Free, total, or fraction-associated fatty acids Defines which fatty acid pool the result represents.
Reporting basis Relative composition, concentration, mass fraction, molar amount, totals, or defined ratios Keeps calculations and comparisons aligned with the study endpoint.
Analytical route GC-FID, GC-MS, or targeted LC-MS/MS Matches platform selectivity and coverage to the matrix and target panel.

Broader projects can connect omega-3 measurements with polyunsaturated fatty acid analysis, a fatty acid profile by GC-FID and GC-MS, or a defined targeted lipidomics panel.

Omega-3 Fatty Acids We Analyze

The final panel is confirmed against the matrix, analytical route, reference standards, and expected abundance. A typical n-3 panel can include the following fatty acids and selected adjacent species needed for interpretation.

Common Name Abbreviation Lipid Shorthand Typical Role in the Panel
Alpha-linolenic acid ALA 18:3 n-3 Essential plant-derived precursor and common ingredient endpoint
Stearidonic acid SDA 18:4 n-3 Intermediate in long-chain n-3 biosynthesis and specialty-oil target
Eicosatrienoic acid ETE 20:3 n-3 Intermediate that may support pathway-focused research
Eicosatetraenoic acid ETA 20:4 n-3 Long-chain n-3 intermediate included in expanded panels
Eicosapentaenoic acid EPA 20:5 n-3 Major marine-derived analyte and frequent primary endpoint
Docosapentaenoic acid, n-3 n-3 DPA 22:5 n-3 Long-chain n-3 analyte between EPA and DHA
Docosahexaenoic acid DHA 22:6 n-3 Major long-chain n-3 analyte in marine oils and biological tissues

Depending on the question, the panel can also include relevant omega-6 fatty acids, saturated and monounsaturated fatty acids, totals by class, and calculated ratios. Ratios are only reported when the numerator and denominator are measured in a compatible workflow and expressed on a consistent basis. Projects requiring a wider compositional context can be extended through our unsaturated fatty acid analysis, while studies focused on downstream oxygenated signaling molecules may benefit from a separate eicosanoid analysis service.

Select GC-FID, GC-MS, or LC-MS/MS

No single platform is automatically best for every omega-3 project. Method selection depends on whether the priority is broad composition, compound confirmation, selective quantification in a complex matrix, or a specific free or total fraction.

Platform Best Fit Measurement Strengths Important Design Considerations
GC-FID Oils, foods, feeds, ingredients, and broad fatty acid composition Robust chromatographic quantification across an established FAME profile; well suited to relative composition and product characterization Fatty acids are commonly converted to methyl esters; peak resolution, response factors, and the reporting basis must be defined
GC-MS Complex profiles that benefit from mass-spectral evidence in addition to retention behavior Adds mass-spectral information for identification support while retaining GC separation of derivatized fatty acids Derivatization and chromatographic separation remain critical; positional isomers can require specialized methods or standards
Targeted LC-MS/MS Selective quantification in biological matrices or studies requiring a defined free/total workflow Matrix-specific selectivity, targeted transitions, and isotope-labeled internal standards where available Extraction, hydrolysis when applicable, matrix effects, calibration design, and analyte coverage require fit-for-purpose evaluation

GC workflows commonly measure fatty acids after conversion to fatty acid methyl esters. When that route fits the objective, our fatty acid methyl ester analysis capabilities can support method planning. Targeted LC-MS/MS may be preferable when a biological matrix, selective analyte set, or free-versus-total distinction calls for a more narrowly defined assay. In either route, we avoid treating platform names as a substitute for assay design: extraction, standards, calibration, chromatographic separation, and QC determine how useful the final result will be.

Decision framework for selecting GC-FID, GC-MS, or LC-MS/MS for omega-3 analysisMethod selection follows the matrix, chemical form, and reporting objective.

Our Omega-3 Analysis Workflow

From Feasibility Review to Analysis-Ready Data

  1. Feasibility and study-design review. We review matrix, species or product type, groups and replicates, priority analytes, expected range, reporting basis, and storage history.
  2. Panel and method selection. The team confirms GC-FID, GC-MS, or LC-MS/MS; free, total, or fraction-associated measurement; analyte coverage; and reference-standard availability.
  3. Sample preparation. A matrix-appropriate extraction is used. GC routes include derivatization to FAMEs when required; total-fatty-acid workflows may include hydrolysis; free-fatty-acid workflows avoid conflating unesterified and esterified pools.
  4. Instrumental analysis. Samples, standards, blanks, and QC materials are organized into an analytical batch with suitability and carryover checks appropriate to the method.
  5. Data processing and QC review. Peaks or transitions are reviewed, internal-standard responses are assessed, calibration and batch behavior are evaluated, and exceptions are documented.
  6. Reporting and interpretation support. Results are delivered in the selected units with a QC summary, method notes, and analysis-ready tables. Comparative statistics and visualizations can be added when the study design supports them.

This workflow is intentionally modular. An oil-composition project may emphasize representative sampling, FAME conversion, peak resolution, and mass-fraction reporting. A plasma study may place more weight on collection consistency, storage history, hydrolysis choice, matrix effects, isotope-labeled internal standards, and concentration units. The common principle is that pre-analytical chemistry and the reporting basis are defined before data generation.

Six-step omega-3 fatty acid analysis workflow from feasibility review to reportingA project-specific path from study design to reviewed data.

Quality Controls for Defensible Quantification

Quality control is matched to the platform and claim. Depending on the project, the analytical plan can include solvent and process blanks, calibration standards, internal standards, pooled or matrix-representative QC samples, replicates, carryover checks, response monitoring, and batch-order controls. Isotope-labeled internal standards are used where they are available and appropriate; when exact analogs are not available, surrogate selection and its limitations are documented.

For absolute quantification, the feasibility review addresses calibration range, standard purity or value assignment, recovery, matrix effects, response behavior, and the suitability of the chosen internal standard. For relative-composition workflows, attention shifts toward chromatographic separation, peak assignment, response-factor treatment, and consistent calculation of the denominator. We do not convert relative peak area into an absolute concentration unless the method and calibration support that interpretation.

The QC summary is designed to help researchers understand whether a batch behaved as intended. It can include calibration performance, blank observations, internal-standard behavior, replicate agreement, drift or carryover observations, and notes on excluded or qualified results. Acceptance criteria are defined during method planning rather than imposed as generic thresholds across unrelated matrices.

Why Researchers Choose Creative Proteomics

  • Question-first method selection: We distinguish composition from concentration and free from total or fraction-associated measurements before platform selection.
  • Multiple analytical routes: GC-FID, GC-MS, and LC-MS/MS options allow the method to follow the matrix and decision instead of forcing every project into one workflow.
  • Transparent assay boundaries: Target coverage, standards, reporting units, and known limitations are agreed upon during feasibility review.
  • QC-forward execution: Batch controls and data review are built into the analytical plan and summarized with the results.
  • Expandable lipid context: Omega-3 measurements can be coordinated with broader lipid panels or oxylipin quantification and pathway profiling when downstream oxygenated metabolites are relevant.
  • Analysis-ready delivery: Data tables, QC information, visual summaries, and optional group comparisons are organized for scientific review and downstream use.

Sample Types and Submission Guidance

Sample Category Examples Planning Considerations
Blood-derived samples Plasma, serum, whole blood, red blood cells Use a consistent collection protocol and anticoagulant where applicable; record processing time and storage history; avoid repeated freeze-thaw cycles
Tissues and cells Animal tissues, biopsies, cultured cells, cell pellets Keep collection and normalization consistent; record wet weight, cell count, protein basis, or another normalization variable
Oils and lipid ingredients Fish, algal, krill, plant, and blended oils Protect from light, heat, and oxygen; provide formulation details, antioxidants, and expected concentration range
Foods, feeds, and raw materials Fortified foods, powders, emulsions, feeds, and ingredients Provide a representative homogenized sample and identify the desired reporting basis, such as per mass of sample, total fat, or total fatty acids
Formulations and test articles Capsules, emulsions, specialty lipids, and research formulations Disclose excipients, carrier oils, encapsulation, and other components that may affect extraction or chromatography

Exact sample amounts and containers are confirmed after the target list and method route are selected. This avoids publishing a universal minimum that may be unsuitable for a low-abundance matrix, a broad panel, repeat analysis, or a stability-sensitive formulation. Samples should be labeled unambiguously, shipped under conditions that preserve their current state, and accompanied by a sample manifest.

For a useful feasibility review, provide the matrix, species or product type, number of groups and replicates, total sample count, priority analytes, expected range if known, free or total measurement preference, requested units, available sample amount, and storage history. Mention any treatments, diets, processing steps, or formulation components that could materially affect interpretation.

Data Package and Reporting Options

The core data package is tailored to the study question and may include:

Quantitative Results

  • Processed analyte tables with sample identifiers, units, and calculation notes.
  • Relative fatty acid composition, absolute concentration, mass fraction, or molar reporting when supported by the selected method.
  • EPA, DHA, ALA, n-3 DPA, total omega-3, selected class sums, and omega-6:omega-3 ratios when specified in the analysis plan.

QC, Methods, and Interpretation

  • A QC summary describing calibration, blanks, internal-standard behavior, replicate observations, and qualified results.
  • Method notes covering extraction, hydrolysis or derivatization, analytical platform, and reporting basis.
  • Optional group comparisons, univariate statistics, heat maps, profile plots, and other study-appropriate visualizations.
  • Editable tables in CSV or XLSX format and report-ready figures in PNG or SVG format, with a PDF summary when requested.
Representative quantitative omega-3 fatty acid profile with EPA, DHA, ALA, and DPA results

Representative quantitative profile delivered as a report-ready visual.

Representative omega-3 analysis quality control and calibration summary

Representative QC summary supporting review of batch performance.

Raw instrument files can be discussed during project planning when they are required for archiving or independent review. Statistical analyses are agreed upon before execution so that group structure, replicate type, missing-value handling, normalization, and multiple-testing considerations are not decided after viewing the results.

Research and Product-Development Applications

  • Nutrition and intervention research: Measure how diets, supplements, genetic models, or experimental interventions change EPA, DHA, ALA, n-3 DPA, total omega-3, or the surrounding fatty acid profile.
  • Oil, ingredient, and formulation characterization: Confirm omega-3 composition in fish, algal, krill, plant, and blended oils; compare lots or formulations; and assess whether processing or storage changes the measured profile.
  • Food and feed research: Characterize fortified foods, feeds, raw materials, and processed products. Representative sampling and homogenization matter when lipids are unevenly distributed. When the unesterified lipid pool is a separate development endpoint, the study can incorporate a dedicated free fatty acid analysis.
  • Preclinical and metabolic studies: Use targeted omega-3 endpoints to support studies of lipid metabolism, tissue distribution, exposure, or response to an intervention.
  • Method transfer and fit-for-purpose development: Evaluate analyte coverage, extraction, calibration, selectivity, and reporting requirements for a new matrix or product.
  • Integrated lipid research: Coordinate omega-3 endpoints with lipid-class-specific, signaling-lipid, or broader pathway measurements when the scientific question requires more context.

Frequently Asked Questions

Can you measure EPA, DHA, ALA, and n-3 DPA in the same project?

Often yes, but the final panel depends on the matrix, platform, expected range, chromatographic behavior, and availability of suitable standards. We confirm the target list during feasibility review and may recommend adjacent fatty acids when they are needed to calculate totals or ratios.

Should I request free or total omega-3 fatty acids?

Choose the fraction that matches the biological question. Free fatty acids represent the unesterified pool at collection. Total-fatty-acid workflows release fatty acids from esterified lipids and therefore measure a broader pool. Some studies instead isolate a fraction, such as plasma phospholipids. These results are not interchangeable.

When is GC-FID preferable to LC-MS/MS?

GC-FID is often a strong choice for broad fatty acid composition in oils, foods, feeds, and other matrices where an established FAME profile is the goal. LC-MS/MS may be preferable for a selective panel in a complex biological matrix, particularly when the study needs matrix-specific calibration or a defined free/total assay. GC-MS is useful when mass-spectral evidence adds value to a GC separation.

Can you report an omega-6:omega-3 ratio?

Yes, when the specified omega-6 and omega-3 analytes are measured on a compatible basis. The project plan defines which species contribute to each sum and whether the ratio is based on relative composition, molar amount, or concentration.

Do you provide a clinical Omega-3 Index result?

No. This page describes a research-use analytical service and is not presented as a clinical Omega-3 Index test. If red blood cells are submitted for research, the analytical scope and reporting basis are defined for the study without diagnostic interpretation.

How should oils and formulations be stored before shipment?

Minimize exposure to heat, light, and oxygen, and keep storage conditions consistent across samples. Provide information about antioxidants, carrier oils, encapsulation, and storage history. The project team will recommend shipment conditions after reviewing the formulation and analysis plan.

What information is needed for a quote?

Provide the matrix, species or product type, groups and replicates, total sample count, priority analytes, expected range if known, desired free or total measurement, reporting units, available sample amount, and storage constraints.

Selected Publications

  1. Muhammad Alinafiah S, Azlan A, Ismail A, Mahmud Ab Rashid N-K. Method Development and Validation for Omega-3 Fatty Acids (DHA and EPA) in Fish Using Gas Chromatography with Flame Ionization Detection (GC-FID). Molecules. 2021;26(21):6592.
  2. Serafim V, Tiugan D-A, Andreescu N, et al. Development and Validation of a LC-MS/MS-Based Assay for Quantification of Free and Total Omega 3 and 6 Fatty Acids from Human Plasma. Molecules. 2019;24(2):360.
  3. Schött H-F, Konings MCJM, Schrauwen-Hinderling VB, Mensink RP, Plat J. A Validated Method for Quantification of Fatty Acids Incorporated in Human Plasma Phospholipids by Gas Chromatography-Triple Quadrupole Mass Spectrometry. ACS Omega. 2021;6(2):1129-1137.
  4. Ren J, Mozurkewich EL, Sen A. Total Serum Fatty Acid Analysis by GC-MS: Assay Validation and Serum Sample Stability. Current Pharmaceutical Analysis. 2013;9(4):331-339.
* Our services can only be used for research purposes and Not for clinical use.

Online Inquiry

CONTACT US

  • USA
  • Tel: 1-631-275-3058 (USA)
  • Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
  • Email:
  • Fax: 1-631-614-7828
  • Germany
  • Address: 65830 Kriftel, Gutenbergstraße 5. Frankfurt am Main, Germany
Copyright © 2026 Creative Proteomics. All rights reserved.